Last Updated: 08 Nov 2024
Executive Summary
Chemours Co (CC) is a leading provider of high performance chemicals globally. The company has a strong financial position with a market capitalization of $30.55 billion, EBITDA of $786 million, and EPS of $0.5. Chemours' stock price is currently trading at $20.45, within its 52-week range of $14.76 and $31.7. The company's fundamentals are solid, with a trailing PE of 40.9 and a forward PE of 7.71. Analysts are generally positive on Chemours, with 4 issuing Buy ratings and 6 issuing Hold ratings. The stock has a Beta of 1.745, indicating higher volatility than the market.
Company Overview
Chemours Co is headquartered in Wilmington, Delaware and offers a wide range of high performance chemicals. The company's products are used in various industries, including automotive, construction, electronics, and industrial. Chemours has a global presence, with operations in North America, Asia Pacific, Europe, the Middle East, Africa, and Latin America.
Fundamental Analysis
Chemours' financial performance has been mixed in recent quarters. Revenue for the latest quarter was $5.75 billion, a 0.009% increase year-over-year. However, quarterly earnings declined by 0.646% to $0.5 per share. The company's profit margin is 1.32%, while its operating margin is 9.86%. Chemours has a strong balance sheet, with total assets of $12.1 billion and total debt of $4.3 billion. The company's return on assets is 3.97%, and its return on equity is 11%.
Technical Analysis
Chemours' stock price has been trending lower in recent months. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is at 35.84, indicating that the stock is oversold. The MACD is also below the signal line, indicating bearish momentum.
Short Term Outlook
In the short term, Chemours' stock price is likely to remain under pressure. The company's earnings growth has slowed, and the technical indicators are bearish. The stock could potentially test its 52-week low of $14.76.
Long Term Outlook
In the long term, Chemours' stock price could recover if the company can improve its earnings growth. The company's fundamentals are solid, and it has a strong market position. However, investors should be aware of the risks associated with the company's high Beta.
Analyst Recommendations
Analysts are generally positive on Chemours. The consensus analyst rating is Buy, with a target price of $25.67. Four analysts have issued Buy ratings, while six have issued Hold ratings. One analyst has issued a Strong Sell rating.
